OBJECTIVE: There is increasing evidence of an association between leptin and increased cardiovascular risk. Higher leptin levels are associated with increased levels of C-reactive protein (CRP), which itself elicits proatherogenic effects in the vascular endothelium. We tested the hypothesis that leptin induces CRP expression in human coronary artery endothelial cells (HCAECs). METHODS AND RESULTS: We confirmed the presence of both long and short isoforms of the leptin receptor in cultured HCAECs. Leptin but not IFNalphaA/D nor tumor necrosis factor (TNF) alpha, induced expression of CRP. A dose dependent increase of CRP mRNA and protein was observed with increasing concentration of leptin (0 to 400 ng/mL). This increased CRP expression was attenuated in the presence of anti-leptin receptor antibodies and also by inhibition of ERK1/2 by PD98059 (20 to 40 micromol/L). Time (0 to 60 minutes) and leptin concentration (0 to 200 ng/mL)-dependence of ERK1/2 phosphorylation were evident in response to leptin treatment. Leptin also elicited ROS generation. Inhibition of ROS by catalase (200 microg/mL) prevented ERK1/2 phosphorylation and CRP mRNA transcription. CONCLUSION: Leptin induces CRP expression in HCAECs via activation of the leptin receptor, increased ROS production, and phosphorylation of ERK1/2. These studies suggest a mechanism for the proatherogenic effects of leptin.
OBJECTIVE: There is increasing evidence of an association between leptin and increased cardiovascular risk. Higher leptin levels are associated with increased levels of C-reactive protein (CRP), which itself elicits proatherogenic effects in the vascular endothelium. We tested the hypothesis that leptin induces CRP expression in human coronary artery endothelial cells (HCAECs). METHODS AND RESULTS: We confirmed the presence of both long and short isoforms of the leptin receptor in cultured HCAECs. Leptin but not IFNalphaA/D nor tumor necrosis factor (TNF) alpha, induced expression of CRP. A dose dependent increase of CRP mRNA and protein was observed with increasing concentration of leptin (0 to 400 ng/mL). This increased CRP expression was attenuated in the presence of anti-leptin receptor antibodies and also by inhibition of ERK1/2 by PD98059 (20 to 40 micromol/L). Time (0 to 60 minutes) and leptin concentration (0 to 200 ng/mL)-dependence of ERK1/2 phosphorylation were evident in response to leptin treatment. Leptin also elicited ROS generation. Inhibition of ROS by catalase (200 microg/mL) prevented ERK1/2 phosphorylation and CRP mRNA transcription. CONCLUSION: Leptin induces CRP expression in HCAECs via activation of the leptin receptor, increased ROS production, and phosphorylation of ERK1/2. These studies suggest a mechanism for the proatherogenic effects of leptin.
Authors: Hans-Joerg Busch; Stephan H Schirmer; Marco Jost; Sylvia van Stijn; Stephan L M Peters; Jan J Piek; Christoph Bode; Ivo R Buschmann; Guenter Mies Journal: J Cereb Blood Flow Metab Date: 2010-10-27 Impact factor: 6.200
Authors: L D'Elia; A Giaquinto; F P Cappuccio; R Iacone; O Russo; P Strazzullo; F Galletti Journal: J Endocrinol Invest Date: 2019-11-05 Impact factor: 4.256
Authors: Carlos M Diaz-Melean; Virend K Somers; Juan Pablo Rodriguez-Escudero; Prachi Singh; Ondrej Sochor; Ernesto Manuel Llano; Francisco Lopez-Jimenez Journal: Curr Atheroscler Rep Date: 2013-11 Impact factor: 5.113
Authors: Prachi Singh; Timothy E Peterson; Kara R Barber; Fatima Sert Kuniyoshi; Andrus Jensen; Michal Hoffmann; Abu S M Shamsuzzaman; Virend K Somers Journal: Biochem Biophys Res Commun Date: 2010-01-05 Impact factor: 3.575